^
    BIOMARKER:
    HER-2 positive
    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    HER-2 positive
    Gastric Cancer
    pembrolizumab + trastuzumab
    Sensitive
    :
    A1
    FDA - 6d
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    pembrolizumab + trastuzumab
    Sensitive
    :
    A1
    FDA - 6d
    HER-2 positive
    Gastric Cancer
    RC48
    Sensitive
    :
    C3
    Gastric Cancer - 1wk
    HER-2 positive
    Gastric Cancer
    trastuzumab-IFN-β mutein
    Sensitive
    :
    D
    AACR 2021 - 4wk
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + tucatinib
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + pertuzumab
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    margetuximab
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    trastuzumab
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    A1
    HER-2 positive
    Gastric Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    fam-trastuzumab deruxtecan-nxki
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    ado-trastuzumab emtansine
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    pertuzumab/trastuzumab/hyaluronidase-zzxf
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Trazimera (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ontruzant (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Ogivri (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Kanjinti (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Herzuma (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    neratinib
    Sensitive
    :
    A1
    HER-2 positive
    Gastroesophageal Junction Adenocarcinoma
    Zercepac (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    HER2 Positive Breast Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    Gastric Cancer
    Zercepac (trastuzumab biosimilar)
    Sensitive
    :
    A1
    HER-2 positive
    Gastric Cancer
    trastuzumab
    Sensitive
    :
    A2
    HER-2 positive
    HER2 Positive Breast Cancer
    TCHP
    Sensitive
    :
    A2
    HER-2 positive
    HER2 Positive Breast Cancer
    TCH
    Sensitive
    :
    A2
    HER-2 positive
    HER2 Positive Breast Cancer
    trastuzumab + lapatinib
    Sensitive
    :
    A2
    HER-2 positive
    GastroEsophageal Cancer
    trastuzumab
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES